文献速递冠心病

客观风险评估与标准治疗对急性冠脉综合征的影响:一项随机临床试验

Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该研究为多中心整群随机PROBE试验,纳入2318例ACS患者,评估常规使用GRACE风险评分(GRS)对指南推荐治疗和临床结局的影响。研究因无效提前终止。

要点

  • GRS实施未显著降低1年死亡或心梗风险(9.2% vs 13.4%,OR 0.66,95%CI 0.38-1.14)。

核心结论

  • 在临床护理水平较高的心内科服务中,常规实施GRS与早期有创治疗增加相关,但未改善其他方面护理。
  • 低事件率和研究提前终止提示需要进一步更大规模的随机研究。

研究设计与样本

  • 前瞻性整群(医院层面)随机开放标签盲法终点(PROBE)临床试验,使用多中心ACS注册登记。
  • 纳入24家医院2318例STEMI或NSTE-ACS患者,2014年6月至2018年3月入组,因无效提前终止。

主要发现

  • 5种指南推荐药物中4种处方率GRS组76.7%(864/1135) vs 对照组77.5%(893/1183),OR 0.97,95%CI 0.68-1.38。
  • 心脏康复转诊率GRS组75.1%(855/1135) vs 对照组72.8%(861/1183),OR 0.68,95%CI 0.32-1.44。
  • 12个月死亡或心梗复合终点GRS组9.2%(96/1044) vs 对照组13.4%(146/1087),OR 0.66,95%CI 0.38-1.14。

临床怎么用

  • 在高水平临床护理机构中,常规GRS实施可能增加早期有创治疗,但未显著改善其他指南推荐治疗或短期临床结局。
  • GRS实施需结合本地实践,不能假定其必然改善所有护理流程。

局限性

  • 研究因无效提前终止,可能影响统计效能。
  • 事件率低,限制了临床结局的评估。
  • 研究在临床护理水平较高的心内科服务中进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Although international guidelines recommend use of the Global Registries of Acute Coronary Events (GRACE) risk score (GRS) to guide acute coronary syndrome (ACS) treatment decisions, the prospective utility of the GRS in improving care and outcomes is unproven. OBJECTIVE: To assess the effect of routine GRS implementation on guideline-indicated treatments and clinical outcomes of hospitalized patients with ACS. DESIGN, SETTING, AND PARTICIPANTS: Prospective cluster (hospital-level) randomized open-label blinded end point (PROBE) clinical trial using a multicenter ACS registry of acute care cardiology services. Fixed sampling of the first 10 patients within calendar month, with either ST-segment elevation or non-ST-segment elevation ACS. The study enrolled patients from June 2014 to March 2018, and data were analyzed between February 2020 and April 2020. INTERVENTIONS: Implementation of routine risk stratification using the GRS and guideline recommendations. MAIN OUTCOMES AND MEASURES: The primary outcome was a performance score based on receipt of early invasive treatment, discharge prescription of 4 of 5 guideline-recommended pharmacotherapies, and cardiac rehabilitation referral. Clinical outcomes included a composite of all-cause death and/or myocardial infarction (MI) within 1 year. RESULTS: This study enrolled 2318 patients from 24 hospitals and was stopped prematurely owing to futility. Of the patients enrolled, median age was 65 years (interquartile range, 56-74 years), 29.5% were women (n = 684), and 62.9% were considered high risk (n = 1433). Provision of all 3 measures among high-risk patients did not differ between the randomized arms (GRS: 424 of 717 [59.9%] vs control: 376 of 681 [55.2%]; odds ratio [OR], 1.04; 95% CI, 0.63-1.71; P = .88). The provision of early invasive treatment was increased compared with the control arm (GRS: 1042 of 1135 [91.8%] vs control: 989 of 1183 [83.6%]; OR, 2.26; 95% CI, 1.30-3.96; P = .004). Prescription of 4 of 5 guideline-recommended pharmacotherapies (GRS: 864 of 1135 [76.7%] vs control: 893 of 1183 [77.5%]; OR, 0.97; 95% CI, 0.68-1.38) and cardiac rehabilitation (GRS: 855 of 1135 [75.1%] vs control: 861 of 1183 [72.8%]; OR, 0.68; 95% CI, 0.32-1.44) were not different. By 12 months, GRS intervention was not associated with a significant reduction in death or MI compared with the control group (GRS: 96 of 1044 [9.2%] vs control: 146 of 1087 [13.4%]; OR, 0.66; 95% CI, 0.38-1.14). CONCLUSIONS AND RELEVANCE: Routine GRS implementation in cardiology services with high levels of clinical care was associated with an increase in early invasive treatment but not other aspects of care. Low event rates and premature study discontinuation indicates the need for further, larger scale randomized studies. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12614000550606.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Chew DP, Hyun K, Morton E, et al. Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 33295965. doi:10.1001/jamacardio.2020.6314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。